NCT05932706

Brief Summary

To investigate the intervention effect of high definition transcranial alternating current stimulation (HD-tACS) on suicidal ideation in patients with depressive disorder and its underlying neural mechanism by magnetic resonance imaging (MRI) and electroencephalography (EEG).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2022

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

May 11, 2023

Completed
2 months until next milestone

First Posted

Study publicly available on registry

July 6, 2023

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 20, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 20, 2025

Completed
Last Updated

January 21, 2026

Status Verified

June 1, 2023

Enrollment Period

2.5 years

First QC Date

May 11, 2023

Last Update Submit

January 17, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in Beck Scale for Suicide Ideation (BSS) Score

    The BSS is a 19-item scale to measure the severity of suicidal ideation, where each item is rated on a scale from 0 to 2. The BSS total score ranges from 0 to 38 with lower scores indicating less suicidal ideation.

    baseline, week 1 (end of treatment), and week 5 (end of follow-up)

Secondary Outcomes (9)

  • Beck Scale for Suicide Ideation (BSS) Response Rate (≥50% Improvement From Baseline)

    week 1 (end of treatment) and week 5 (end of follow-up)

  • Change in Columbia-Suicide Severity Rating Scale (C-SSRS) Score

    baseline, week 1 (end of treatment), and week 5 (end of follow-up)

  • Change in Hamilton Depression Rating Scale (HAMD) Score

    baseline, week 1 (end of treatment), and week 5 (end of follow-up)

  • Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Score

    baseline, week 1 (end of treatment), and week 5 (end of follow-up)

  • Change in Beck Depression Inventory (BDI) Score

    baseline, week 1 (end of treatment), and week 5 (end of follow-up)

  • +4 more secondary outcomes

Study Arms (2)

real stimulation

ACTIVE COMPARATOR

The central electrode was placed over F3, with return electrodes at Fp1, Fz, F7 and C3. Fourteen 2-mA sessions (ramp-up and ramp-down periods of 15 and 15 seconds, respectively) were applied for 30 minutes per session, twice daily over 7 consecutive days, and the stimulus frequency was set as IAF.

Device: High definition transcranial alternating current stimulation

sham stimulation

SHAM COMPARATOR

In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (15 and 15 s); no current was delivered during the 30-minute intervention. Participants will receive sham tACS twice daily for two weeks.

Device: sham high definition transcranial alternating current stimulation

Interventions

tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.

real stimulation

In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (15s and 15s); no current was delivered during the 30-minute intervention.

sham stimulation

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • the patients were diagnosed by more than 2 psychiatrists and met the diagnostic criteria of DSM-5 for depression, and item 3 of the HAMD≥3.
  • the age ranged from 18 to 65 years old, and the length of education was more than 5 years.
  • the visual acuity or corrected visual acuity is normal, right-handed, can cooperate with the completion of various experimental tests.

You may not qualify if:

  • accompanied by severe somatic diseases, such as severe heart, liver, renal insufficiency and so on.
  • accompanied by other neurological diseases, such as stroke, epilepsy and so on. pregnant and lactating women.
  • accompanied by other mental disorders, such as drug abuse, schizophrenia, schizophrenic affective

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Yanghua Tian

Hefei, Anhui, 230022, China

Location

MeSH Terms

Conditions

Depressive Disorder

Condition Hierarchy (Ancestors)

Mood DisordersMental Disorders

Study Officials

  • Yanghua Tian, PhD

    Anhui Medical University

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of medical psychological department, Anhui Medical University

Study Record Dates

First Submitted

May 11, 2023

First Posted

July 6, 2023

Study Start

September 1, 2022

Primary Completion

February 20, 2025

Study Completion

February 20, 2025

Last Updated

January 21, 2026

Record last verified: 2023-06

Locations